Selected data models

You must log in to select data models for download or further analysis.

33 Search results.
Relevance Rating New first Old first

Eligibility Recurrent Pediatric ALL NCT00439296

- 6/14/17 - 1 form, 3 itemgroups, 8 items, 1 language
Itemgroups: Criteria, Inclusion Criteria, Exclusion Criteria
ABT-751 With Chemotherapy for Relapsed Pediatric ALL; ODM derived from: https://clinicaltrials.gov/show/NCT00439296

SAE documentation AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - SAE documentation AIEOP-BFM ALL 2009 NCT01117441

- 3/15/21 - 1 form, 4 itemgroups, 39 items, 1 language
Itemgroups: Patient Information, Therapy, Severe adverse event, Identification and Signature
Study Description Stamm: International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation. Clinical Trial Number: NCT01117441.

Laboratory Parameters R-R2 AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Laboratory Parameters R-R2 AIEOP-BFM ALL 2009 NCT01117441

- 5/15/16 - 1 form, 4 itemgroups, 17 items, 1 language
Itemgroups: Patient Information, Laboratory Parameters Study Section, Laboratory Parameters Control Section, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Laboratory documentation. Clinical Trial Number: NCT01117441.

Laboratory Parameters R-HR AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Laboratory Parameters R-HR AIEOP-BFM ALL 2009 NCT01117441

- 5/15/16 - 1 form, 4 itemgroups, 17 items, 1 language
Itemgroups: Patient Information, Laboratory Parameters Study Section, Laboratory Parameters Control Section, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Laboratory documentation. Clinical Trial Number: NCT01117441.

HR-3 therapy documentation AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - HR-3 therapy documentation AIEOP-BFM ALL 2009 NCT01117441

- 5/9/16 - 1 form, 4 itemgroups, 29 items, 1 language
Itemgroups: Patient Information, Chemotherapy Regimen, PEG-L-ASP/ Erwinase, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation part. Clinical Trial Number: NCT01117441.

DNX-FLA regimen AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - DNX-FLA regimen AIEOP-BFM ALL 2009 NCT01117441

- 5/9/16 - 1 form, 3 itemgroups, 19 items, 1 language
Itemgroups: Patient Information, Chemotherapy Regimen, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation part. Clinical Trial Number: NCT01117441.

HR-2 therapy documentation AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - HR-2 therapy documentation AIEOP-BFM ALL 2009 NCT01117441

- 5/9/16 - 1 form, 4 itemgroups, 39 items, 1 language
Itemgroups: Patient Information, Chemotherapy Regimen, PEG-L-ASP/ Erwinase, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation part. Clinical Trial Number: NCT01117441.

HR-1 therapy documentation AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - HR-1 therapy documentation AIEOP-BFM ALL 2009 NCT01117441

- 5/9/16 - 1 form, 4 itemgroups, 38 items, 1 language
Itemgroups: Patient Information, Chemotherapy Regimen, PEG-L-ASP/ Erwinase, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation part. Clinical Trial Number: NCT01117441.

Documentation of therapy toxicity AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Documentation of therapy toxicity AIEOP-BFM ALL 2009 NCT01117441

- 5/31/16 - 1 form, 6 itemgroups, 25 items, 1 language
Itemgroups: Patient Information, Therapy, Blood analysis, Toxicity, Comments, Identification and Signature
Study Description Stamm: International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation of therapy toxicity. Clinical Trial Number: NCT01117441.

Maintenance therapy R2 AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Maintenance therapy R2 AIEOP-BFM ALL 2009 NCT01117441

- 3/15/21 - 1 form, 3 itemgroups, 21 items, 1 language
Itemgroups: Patient Information, Examinations, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation part. Clinical Trial Number: NCT01117441.

Protocol medication AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Protocol medication AIEOP-BFM ALL 2009 NCT01117441

- 7/14/16 - 1 form, 14 itemgroups, 57 items, 1 language
Itemgroups: Patient Information, First Element, Second Element, Third Element, Fourth Element, Fifth Element, Sixth Element, Seventh Element, Eighth Element, Ninth Element, Cranial radiation, Maintenance treatment, Comments, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation of administered protocol medication Clinical Trial Number: NCT01117441.

Initial survey AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Initial survey AIEOP-BFM ALL 2009 NCT01117441

- 5/15/16 - 1 form, 9 itemgroups, 103 items, 1 language
Itemgroups: Patient Information, Anamnesis, Diagnosis, Blood analysis, Initial CNS status, Multi-organ involvement, Prednisone response, Comments, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Initial survey. Please send this document within one month after diagnosis to the study centre. Clinical Trial Number: NCT01117441.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial